Table 2. Adverse events.

Adverse Event	Grade 1	Grade 2	Grade 3-4
Rash acneiform	6 (40%)	2 (13%)	0
Fatigue	4 (27%)	0	1 (7%)
Alkaline phosphatase elevation	0	2 (13%)	3 (20%)
Arthralgias	2 (13%)	2 (13%)	0
Dry skin/xerosis	4 (27%)	0	0
AST/ALT elevation	0	0	3 (20%)*
Photosensitivity	2 (13%)	1 (7%)	0
Nausea	1 (7%)	1 (7%)	0
Erythema multiforme	2 (13%)	0	0
Pruritis	2 (13%)	0	0
Rash maculopapular	2 (13%)	0	0
Neutropenia	0	0	1 (7%)
Keratosis	0	1 (7%)	0
Palmar-plantar erythrodysesthesia syndrome	0	1 (7%)	0
Weight loss	0	1 (7%)	0
Alopecia	1 (7%)	0	0
Diarrhea	1 (7%)	0	0
Hypomagnesemia	1 (7%)	0	0
Nasal vestibulitis	1 (7%)	0	0

^*Grade 4 AST/ALT elevations were noted twice in the same patient, occurring after initial treatment and on re-challenge with vemurafenib.